This protocol is the next clinical step in our biochemical assessment of a cell therapy approach to treat Chronic Limb Threatening Ischemia (CLI). Briefly, the capability to enlarge collateral arteries ("arteriogenesis"), and to stimulate growth of new capillaries, arterioles and venules at the tissue level ("angiogenesis") is innate. Investigators attribute the failure for this to occur in CLI to the ischemic environment. In our first protocol investigators used an external programmed pneumatic compression device (Art-Assist Device) to improve hemodynamics in the limb and most importantly to provide the "on-switch" to activate the endothelium so arteriogenesis can begin. This new protocol provides the second step in improving this environment; improving the cellular deficit and protein signaling. Investigators are seeking the proteomic, biochemical, and cytometry data needed to refine the approach so a clinical trial can be performed. This project will use FDA approved and CMS reimbursed products.